Apoptotic pathways in pancreatic ductal adenocarcinoma

Rainer Hamacher, Roland M. Schmid, Dieter Saur, Günter Schneider

Research output: Contribution to journalReview articlepeer-review

115 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most common causes of cancer related death. Despite the advances in understanding of the molecular pathogenesis, pancreatic cancer remains a major unsolved health problem. Overall, the 5-year survival rate is less than 5% demonstrating the insufficiency of current therapies. Most cytotoxic therapies induce apoptosis and PDAC cells have evolved a plethora of molecular mechanisms to assure survival. We will present anti-apoptotic strategies working at the level of the death receptors, the mitochondria or involving the caspase inhibitors of the IAP family. Furthermore, the survival function of the phosphotidylinositol-3′ kinase (PI3K)/AKT- and NF-kappaB-pathways are illustrated. A detailed molecular knowledge of the anti-apoptotic mechanisms of PDAC cells will help to improve therapies for this dismal disease and therapeutic strategies targeting the programmed cell death machinery are in early preclinical and clinical development.

Original languageEnglish
Article number64
JournalMolecular Cancer
Volume7
DOIs
StatePublished - 24 Jul 2008

Fingerprint

Dive into the research topics of 'Apoptotic pathways in pancreatic ductal adenocarcinoma'. Together they form a unique fingerprint.

Cite this